Specify a stock or a cryptocurrency in the search bar to get a summary
Lipigon Pharmaceuticals AB
LPGOLipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden. Address: TvistevAegen 48 C, Umeå, Sweden, 90736
Analytics
WallStreet Target Price
18.82 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures LPGO
Dividend Analytics LPGO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LPGO
Stock Valuation LPGO
Financials LPGO
Results | 2019 | Dynamics |